Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Monoclonal antibody therapy for breast cancer: herceptin.

× No keyword cloud information.

7 in total

1. A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors.

Authors: Laura Menotti; Arianna Cerretani; Gabriella Campadelli-Fiume
Journal: J Virol Date: 2006-06 Impact factor: 5.103

2. Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib.

Authors: Daniel Medina; Frances Kittrell; Jamal Hill; Yun Zhang; Susan G Hilsenbeck; Reid Bissonette; Powel H Brown
Journal: Cancer Prev Res (Phila) Date: 2009-01-27

3. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.

Authors: Anna Kruschinski; Andreas Moosmann; Isabel Poschke; Håkan Norell; Markus Chmielewski; Barbara Seliger; Rolf Kiessling; Thomas Blankenstein; Hinrich Abken; Jehad Charo
Journal: Proc Natl Acad Sci U S A Date: 2008-11-05 Impact factor: 11.205

4. Strategy escalation: an emerging paradigm for safe clinical development of T cell gene therapies.

Authors: Richard Paul Junghans
Journal: J Transl Med Date: 2010-06-10 Impact factor: 5.531

5. Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice.

Authors: Min Wu; Lina Jung; Adrian B Cooper; Christina Fleet; Lihao Chen; Lyne Breault; Kimberly Clark; Zuhua Cai; Sylvie Vincent; Steve Bottega; Qiong Shen; Andrea Richardson; Marcus Bosenburg; Stephen P Naber; Ronald A DePinho; Charlotte Kuperwasser; Murray O Robinson
Journal: Proc Natl Acad Sci U S A Date: 2009-04-15 Impact factor: 11.205

6. Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours.

Authors: J Green; M Ikram; J Vyas; N Patel; C M Proby; L Ghali; I M Leigh; E A O'Toole; A Storey
Journal: Br J Cancer Date: 2006-05-22 Impact factor: 7.640

7. Fully human HER2/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer.

Authors: Yan Zhou; Lan-Tu Gou; Zhi-Hui Guo; Hai-Rong Liu; Jiang-Man Wang; Shu-Xian Zhou; Jin-Liang Yang; Xiao-An Li
Journal: Mol Med Rep Date: 2015-03-05 Impact factor: 2.952

7 in total